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Abstract This study aims to compare the use and cost of
objective and subjective measures of adherence to pediatric
antiretroviral treatment in a primary care facility in South
Africa. In a 1-month longitudinal study of 53 caregiver-
child dyads, pharmacy reﬁll (PR), measurement of returned
syrups (RS), caregiver self-report (3DR) and Visual Ana-
logue Scale (VAS) were compared to Medication Event
Monitoring System (MEMS). Adherence was 100% for
both VAS and 3DR; by PR and RS 100% and 103%,
respectively. MEMS showed that 92% of prescribed doses
were administered, but only 66% of these within the cor-
rect 12-hourly interval. None of the four measures corre-
lated signiﬁcantly with MEMS. MEMS data suggest that
timing of doses is often more deviant from prescribed than
expected and should be better addressed when monitoring
adherence. Of all, MEMS was by far the most expensive
measure. Alternative, cheaper electronic devices need to be
more accessible in resource-limited settings.
Keywords Adherence   Monitoring methods   Pediatrics  
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Introduction
An estimated 2.1 million children were living with HIV in
2007, 90% of whom were in Sub-Saharan Africa [1].
Combination antiretroviral therapy (ART) has transformed
pediatric HIV from a disease with 50% mortality before
2 years of age into a chronic illness in high-income settings
[2, 3] and increasingly in the developing world [4].
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DOI 10.1007/s10461-010-9825-6Adherence to therapy is vital to preventing resistance and
maintaining the effectiveness of ART regimens [5]. Adher-
ence to ART is a challenge, particularly for children [6].
Children rely on a caregiver, who often is also infected, to
administer medication. Syrups are difﬁcult to measure and
frequentlyunpalatable.Thesechallengesmaybeexacerbated
in resource-limited settings (RLS) that are most affected by
theHIVepidemic.Oftenelderlyfamilymembershavetocare
for children whose biological parents have passed away, and
endupbeingburdenedwithmultipledependentswhilebeing
frail themselves. Extreme ﬁnancial insecurities force care-
giverstoworkinmultipletemporaryemployments,makingit
difﬁcult to stick to a consistently managed medication sche-
dule. The pressures of guaranteeing day-to-day survival in
poor areas may overshadow the long-term goal of adherence
to medication. With this in mind, adherence is even more
crucialinmostpartsofthedevelopingworld,whereonlyone
or two ART regimens are available, leaving limited or no
options once resistance has developed.
Although there is literature surrounding pediatric
adherence in the developed world [7–9], fewer data exist
from sub-Saharan African settings [10]. Data from Cape
Town suggest that adherence, as measured by Medication
Event Monitoring System (MEMS), may be as good or
better than in the developed world [11]. In other African
countries adherence was similarly good, however these
studies primarily used caregiver report or pill count as
adherence measures [12–14]. A heterogeneous array of
pediatric adherence measures and metrics has been used in
RLS, leading to incomparable study outcomes [10].
Although viral load is often used as a surrogate marker of
good adherence, viral load data is not always available in
RLS, and some common regimens, especially those con-
taining protease inhibitors, can be more ‘‘forgiving’’ of poor
adherence to the extent that VL may still be suppressed in
the face of poor short-term adherence [15–17]. While, in
adults, pharmacy reﬁll data seems to correlate well with
virologic suppression and time-to-death in African settings
[18, 19], this measure has not been evaluated for liquid
formulations. Of all adherence measures regularly used,
MEMS appear to provide the closest correlation with viral
load [20] and was used as the reference method for mea-
suring adherence in this study. MEMS has been shown to be
a more accurate adherence measure than self-report and
provides the exact time that the cap was removed [7],
provided that it is used correctly; i.e. closed promptly after
removal without periods of it being kept open.
There have been few comparisons of adherence mea-
sures among children [21] and almost none in sub-Saharan
Africa. Self-report is commonly used, and although readily
available and inexpensive, its validity has often been
questioned [21]. Objective measures like MEMS, on the
other hand, are either not readily available or simply
prohibitively expensive to be used outside of well-resour-
ced research settings [11].
To our knowledge, there has been no cost analysis of
adherence measures for children. With the ongoing
expansion of ART programs, an accurate, cost-effective
method for measuring adherence among children in RLS is
needed. Adherence needs to be closely monitored to detect
early non-adherence and prevent the subsequent develop-
ment of resistance—even more so in settings with limited
treatment options.
This study compared four readily available measures of
pediatric adherence to MEMS in order to assess adherence
behavior and ﬁnd the most accurate and feasible method
for a RLS. It aims to identify adequate methods of adher-
ence measurement for ongoing and future pediatric ART
programs and program-related research.
Methods
Setting
The study took place at the Hannan Crusaid Treatment
Center (HCTC) in the Nyanga district of Cape Town, which
has approximately 300,000 inhabitants and a 28% antenatal
HIV seroprevalence [22]. When meeting the criteria to start
ART (recurrent hospitalizations for HIV-related disease,
modiﬁed WHO stage II or III disease, CD4\20% or
CD4\15% in children under or over 18 months old
respectively [23]), most children are commenced on non-
nucleoside reverse transcriptase inhibitor-based regimens,
usually stavudine (d4T), lamivudine (3TC) and efavirenz
(EFV) or nevirapine (NVP). A lopinavir/ritonavir-based
therapy (LPV/r) is offered for those who had NNRTI-based
Prevention of Mother-To-Child-Transmission Therapy
(PMTCT), fail ﬁrst line treatment or are on Rifamycin-
based antituberculous treatment and are below 3 years of
age. All regimens, with the exception of EFV, are admin-
istered twice daily. Routine follow-up is monthly to month
4 and then every 4 months. VL and CD4 counts are
obtained every 4 months. At the time of this study, 185
children and 1750 adults were receiving ART at the center.
Adherence support is a central component of pediatric
HIV care. Caregivers attend three group ‘‘treatment readi-
ness’’ sessions in order to ensure treatment preparedness.
Trained therapeutic counselors are responsible for up to 120
patients each. Home visits occur at set intervals, with fre-
quency decreasing over time and with success on therapy.
Design
We conducted a 1-month longitudinal study, which
was approved by the Health Sciences Research Ethics
AIDS Behav (2011) 15:422–431 423
123Committee of the University of Cape Town. Children and
caregivers who attended the clinic during July and August
2007 received information about the study in their home
language and were enrolled after written informed consent.
The caregiver contact was managed by a research-trained
nurse in the preferred language of the caregiver. This nurse
did not belong to the regular clinic staff, in order to min-
imize the risk of obtaining answers inﬂuenced by social
desirability or fear of negative treatment repercussions.
Sample
In June and July 2007, 55 eligible caregiver-child dyads
were approached to participate in the study. Inclusion cri-
teria were child age less than 7 years (to focus on the
speciﬁc adherence challenges in this young age group
which makes up 69% of the clinic’s pediatric patients),
having one designated caregiver with appropriate cognitive
ability who consented to be enrolled, and receiving either
lamivudine or abacavir in syrup form (as all other liquid
antiretrovirals required large volumes and did not ﬁt into
one MEMS bottle).
Measurements
Clinical histories were collected from the medical records.
These included age, ART regimen and date of initiation,
WHOstageattreatmentinitiation,changestoARTregimen,
and most recent CD4 percentages and VL (within 6 months
of enrolment). Caregivers completed a basic demographic
questionnaire at the enrollment visit, recording caregiver
age, gender, ethnic and language background (black, ‘‘col-
oured’’ or white South African, primary language at home),
relationship to child (biological mother/father/grandmother,
extended family or other) and ART status.
We used ﬁve adherence measures, of which four could
routinely be used in clinical settings with limited resources:
MEMS as the method of reference; Visual Analog Scales
(VAS); 3 Day Recall of missed doses (3DR); Pharmacy
Reﬁll data (PR); and measurement of returned syrups (RS).
Adherence was described as a continuous variable as well
as a binary variable with a 95% cut-off, based on current
literature [5]. The next routine viral load and CD4 per-
centage taken post-study were also recorded.
Medication Event Monitoring System (MEMS)
Each participant was equipped with a MEMS cap (Aardex
Corp., Zug, Switzerland) for a 1-month period. The cap
records time and date of all bottle-opening events as pre-
sumptive doses taken by the patient; the data is stored in
the chip until downloaded onto a computer. The cap was
ﬁtted on one of the three liquid antiretroviral (ARV) drugs.
Decanting of this drug into the MEMS-equipped bottle was
performed at the clinic pharmacy when patients ﬁlled their
monthly prescriptions. Caregivers received information on
the correct handling and were informed that their adher-
ence would be monitored by MEMS. The speciﬁc mecha-
nism was not revealed to avoid deliberate cap opening
without drug administration.
At the follow-up visit caregivers completed a ques-
tionnaire about their MEMS handling habits, based on the
tool used by Deschamps et al. [24]. Data were downloaded
using PowerView 3.3 (Aardex Corp., Zug, Switzerland),
reviewed manually, compared to the handling question-
naire, and adjusted if necessary. For example, days with
reported non-use of MEMS (but with ART from another
container) were excluded from the analysis as were times
when the MEMS-monitored drug was not immediately
administered after dispensing from the bottle. If two
opening events occurred within an hour, the latter was
excluded (as introduced by Bova et al. [25]). Caregivers
who reported contemporaneous use of the MEMS-moni-
tored ARV from an additional medication bottle were
excluded from the analysis. MEMS has recently been used
in a similar population in Cape Town where it was sig-
niﬁcantly correlated to virologic outcome [11]. Adherence
was deﬁned as:
dosesprescribed   dosesmissed
doses prescribed
  100
Adherence descriptions created were
(i) The overall percentage of doses taken during the
4 week monitoring interval (overallMEMS) and
(ii) The percentage of doses that were taken at the
prescribed 12-h intervals during the whole monitoring
period (with a 2-h window allowed: 1 h before and
1 h after the target dose time; timedMEMS).
Visual Analogue Scale (VAS)
At the 1-month follow-up visit and following the MEMS
monitoring period, all caregivers were asked to rate their
adherence on a Visual Analogue Scale for the previous
month, ranging from 0 to 100%, in bands of 10%, marked
on a vertical line. The scale was administered by the
research assistant and available in English and isiXhosa.
VAS has shown valid results in adults in Uganda [26],
however it seemed less reliable in a pediatric cohort in
Cape Town [11].
Caregiver 3-Day Recall (3DR)
At the 1-month follow-up visit after the MEMS monitor-
ing, caregivers were also asked about their medication-
424 AIDS Behav (2011) 15:422–431
123administering behavior over the past 3 days. For this
information, an adapted and translated version of the recall
questionnaire developed by the Pediatric AIDS Clinical
Trials Group (PACTG) [27] was used. Our version in
isiXhosa recorded information on the number of doses
missed for each ARV drug over the past 3 days and the
reasons for missing them. To our knowledge, the PACTG
had not been used in resource-limited settings before. Data
were expressed both in comparison to the MEMS reports
and as a percentage of adherence calculated:
dosesprescribed   dosesmissed
doses prescribed
  100
Pharmacy Reﬁll (PR)
For all participants, data on previously dispensed medica-
tion was collected for the 4 months preceding enrollment
(thus expecting 5 dispenses) using the clinic pharmacy’s
Intelligent Dispensing of ART software system (iDart, open
source software developed by Cell-Life: www.cell-life.org)
and medical records. We recorded both the number of
times that medication was dispensed and the interval
between dispensing visits in days. All children received
their ART at the clinic’s in-house pharmacy. There were no
other points of ART provision for our patients and ART
was dispensed once a month. Unused medication was
returned to be measured by the adherence counselors and
then disposed. There were no stock-outs during the moni-
tored period. Adherence was calculated as:
Nachega and colleagues demonstrated that pharmacy
reﬁll-measured adherence predicted survival times in a
cohort of adults in Soweto, South Africa [18].
Measurement of Returned Syrups (RS)
Patients were dispensed originally packaged medication
containers, even if these exceed their amount of medication
needed for the subsequent month. Caregivers were asked to
return all of the previously dispensed medication containers
and bottles to assess the amount of medication left. Adher-
ence counselors were trained to measure the amount of RS
using a measuring cylinder. Adherence was calculated as:
This method has been used in conjunction with pill
count in another South African study, where adherence was
associated with virologic outcome [28].
Treatment Outcome
At the study site, CD4% and VL specimens were routinely
collected every 4 months. Since funding restraints did not
allow for us to perform study-speciﬁc blood tests, we
collected the latest CD4% and VL results before study
enrolment as well as the earliest ones after ﬁnishing the
study from the patient records. HIV RNA was measured
using the Bayer HIV-1 RNA 3.0 assay. Children were
deﬁned as having achieved virologic suppression if there
were fewer than 50 copies of HIV RNA/ml in the blood
sample (HIV RNA log\1.69).
Cost Calculation
Costing of the adherence measures used an ingredients-
based methodology in order to most accurately assess the
cost of the measures [29]. This involves measuring the
utilization of person-time and goods (the ingredients)
required to perform the task, and the cost of each ingre-
dient. For each adherence measure all tasks performed by
staff members over and above standard practice in the
absence of adherence measurement were determined.
Measurement of returned syrups was excluded from the
costing analysis for logistical reasons—the research assis-
tant could not measure more than one action at the time.
For each task, the research assistant observed a consecutive
convenience sample of events, recording the time taken to
perform the task and all consumables and other resources
used. The costs of staff time were based on the annual cost
of employment of the staff grade performing the task,
divided by the number of minutes they were expected to
work in each year. The costs of other resources were based
on commercial prices and the costs of durable items were
depreciated across their expected lifetime. It was assumed
that each patient was measured at each of their three
scheduled visits to the clinic annually and where items
were shared across all patients (i.e. the MEMS USB
occasionswhenmedicationwasdispensed
occasions when medication was supposed to be dispensed
  100
amountof syrupdispensed   amountof syrupreturned ðÞ inml
amount of syrup dispensed in ml
  100
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123communicator and software) the cost per patient was based
on the total clinic population at the end of August 2008
(2,304). Overhead costs of building infrastructure and
program management were not included in this costing
since these would be very similar across all adherence
measures and comprise a very small proportion of the total
cost of this clinic [30]. The total annual cost of each
adherence measure was calculated by summing the annual
costs for all ingredients. All costs were converted to US
dollars at the average exchange rate for the South African
Rand and Euro in 2007 (http://www.oanda.com/convert/
fxhistory). In the absence of any gold standard against
which to evaluate effectiveness, no attempt to conduct a
cost-effectiveness analysis was made, and a cost compar-
ison was performed instead.
Statistical Analyses
Descriptive statistics were used to analyze children’s and
caregivers’ characteristics and variables related to treat-
ment outcome. Normally distributed continuous variables
were described using means and standard deviations (SD);
non-normally distributed ones using medians and inter-
quartile ranges (IQR). Discrete data were described using
counts and percentages. To express adherence as a binary
variable, the deﬁned cut-off value was at 95% of the
continuous data for all measures. Patients above this cut-off
were deﬁned as adherent, patients below as non-adherent.
We used Pearson correlations to compare adherence mea-
sures and linear regression to assess the associations
between adherence and treatment outcome. The perfor-
mance criteria for all adherence measures were calculated
with two-by-two tables and receiver operating character-
istic curves. The level of signiﬁcance for all analyses was
P\0.05. All statistical analyses were performed using
STATA 9.0 (StataCorp, College Station, TX).
Results
Characteristics of Caregivers and Children
Two caregivers declined participation such that 53 care-
giver-child dyads were enrolled. These 53 dyads consti-
tuted 56% of the 95 children coming in for a physician visit
during these 2 months, and 29% of all pediatric patients.
The median age of children was 3.7 years (IQR, 3–7) and
53% were female (n = 28). They had been on ART for a
median time of 20 months (IQR, 15–32). Most children
had started ART with late stage HIV-disease—WHO stage
3o r4( n = 37, 71%)—and were receiving ﬁrst-line ART
(n = 50, 94%; regimen details see Table 1). The median
VL was \50 copies/ml both before and after the study
(IQR 50 for both, P\0.5; for number of children with
undetectable viral load see Table 1). There was no signif-
icant change in CD4 count pre-and post-study (t =- 3.4,
P = 0.9; Table 1). CD4% were available for all children at
enrollment and follow-up visits and the virologic data for
all but one child at follow-up due to insufﬁcient sample for
analysis. MEMS adherence data was available for 46
children, VAS and RS data for 48, 3DR data for 49 and PR
for all 53.
Of the caregivers, 40 were the children’s biological
mothers (75%), eight were grandmothers (15%), two each
were fathers and aunts (4%), and one was an older sibling
(2%). The median age of caregivers was 30 years (IQR,
26–37), and 33% (n = 17) were enrolled on ART at the
center themselves. All caregivers spoke isiXhosa as their
ﬁrst language.
Adherence
Medication Event Monitoring System
MEMS cap data were available for 46 children with a mean
monitoring period of 29 days (SD 4.8). For 7 children,
MEMS data were unavailable because of reported loss of
cap (n = 2), of cap non-return due to a different caregiver
at follow-up (n = 3) and because caregivers had reﬁlled
the MEMS syrup into a smaller container for travel
(n = 2). In six cases (13%) data were adjusted as described
above. The median percentage of doses taken during the
Table 1 Demographic characteristics of the children
Pre-study medians
(IQR) or n (%)
a
Post-study medians
(IQR) or n (%)
a
Age (years) 3.7 (3.0–7.0) –
Gender (female), n (%) 28 (53) –
Time on ART (months) 20 (15–32) –
Median viral load (log10) 1.69 1.69
Viral load\50 copies/ml 43 (81) 37 (70)
CD4 (%) 30 (23–33) 32 (27–33)
WHO stage at ART initiation
III, n (%) 26 (49) –
IV, n (%) 11 (21) –
ART regimen
d4T/3TC/LPV/r, n (%) 20 (38) –
d4T/3TC/EFV, n (%) 19 (36) –
AZT/3TC/LPV/r, n (%) 6 (11) –
AZT/3TC/EFV, n (%) 3 (6) –
Other 5 (9) –
ART Antiretroviral treatment, d4T Stavudine, 3TC Lamivudine,
LPV/r Lopinavir/ritonavir, EFV Efavirenz, AZT Zidovudine
a Results presented are median values with inter-quartile ranges,
unless otherwise stated
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123monitoring period was 92% (overallMEMS; IQR, 85–99;
Table 2). Only 66% of doses (IQR, 50–79) were adminis-
tered within the recommended 12-h intervals (timedM-
EMS). When MEMS was adjusted for correct timing, it
showed that 73% of children (n = 33) had adherence
levels of less than 80%. Adherence rates by all measures
did not differ between children with and without MEMS
data.
Visual Analogue Scale
Medication-administering adherence as self-rated by care-
givers on the VAS was 100% for all participants (Table 2).
Three Day Recall
Ninety-two percent of caregivers (n = 45) reported not
having missed any dose in the 3 days prior to the follow-up
visit. One caregiver reported to have missed one dose, one
had missed 3 doses, one 4 doses and one 5 doses. The mean
number of missed doses for all children over the whole
monitoring period was 0.3 (SD, 1.0). Median 3DR adher-
ence was 100% (IQR, 100; Table 2).
Pharmacy Reﬁll
Median adherence by pharmacy records was 100% (IQR,
100). The expected interval between reﬁll visits was
28 days, and 24 caregivers (45%) adhered to their sched-
uled visits. Seven caregivers (13%) were 1 day late, three
caregivers (6%) were 3 days late and ﬁve caregivers (9%)
were more than 4 days late. Thirteen caregivers (25%)
picked up their reﬁlls ahead of the scheduled time
(Table 2).
Measurement of Returned Syrups
In 32 children (67%), RS showed an adherence rate greater
than 100%. Adherence for the MEMS-monitored ARV
drug was 104% (IQR, 98–116), 100% (IQR, 93–101) for
the second ARV drug and 101% (IQR, 99–107) for the
third ARV drug (Table 2).
Adherence as a Categorical Variable
Table 2 shows the classiﬁcation of patients into adherence
groups for each adherence measure. MEMS was the only
measure that reported median adherence rates below 100%,
and the only method that detected substantial numbers of
caregivers with low adherence rates. Only 4 caregivers
(9%) were[95% adherent with regards to correct timing of
doses within the 12-hourly interval.
Comparison of Adherence Measures
Correlations Between Measures
Both MEMS measures were highly correlated with one
another (r = 0.80, P\0.05). RS and 3DR both correlated
with VAS, which correlated with timedMEMS (Table 3).
3-Day Recall and MEMS
The number of doses that caregivers reportedly missed by
3DR was compared with the MEMS data for these days
(n = 46 due to the smaller group of children with MEMS
Table 2 Reported adherence and groups of above 95% and below 80% adherence, by measure
Method Overall adherence (%), median (IQR) [95% adherent n (%) \80% adherent n (%)
overallMEMS 92 (85–99) 16 (36) 8 (18)
timedMEMS 66 (50–79) 4 (9) 33 (73)
3DR 100 (100) 45 (92) 2 (4)
VAS 100 (100) 43 (90) 2 (4)
PR 100 (100) 49 (92) 0
RS 103 (99–106) 43 (90) 1 (2)
MEMS Medication event monitoring system, 3DR 3-Day recall, VAS Visual analogue scale, PR Pharmacy reﬁll, RS Measurement of returned
syrup, IQR Interquartile range
Table 3 Correlation between adherence measures, rho correlation
coefﬁcients
Measure VAS 3DR PR RS
overallMEMS 0.30 0.16 0.01 0.25
timedMEMS 0.32
a 0.19 0.12 0.18
VAS – 0.49
a -0.04 0.54
a
3DR 0.49
a – 0.11 0.08
PR -0.04 0.11 – 0.01
RS 0.54
a 0.08 0.01 –
MEMS Medication event monitoring system, VAS Visual analogue
scale, 3DR 3-Day recall, PR Pharmacy reﬁll, RS Measure of returned
syrup
a P\0.05
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123data; MEMS data was available for all caregivers who
reported less than 100% adherence). While 85% of the
caregivers had reported not to have missed any dose, this
was conﬁrmed by MEMS in only 43% of cases. MEMS
consistently showed higher rates of missed doses than 3DR
caregiver report; 17% for one missed dose (2% by 3DR),
9% for 2 missed doses (2% by 3DR), and 15% for more
than 2 missed doses (0% by 3DR).
MEMS and Treatment Outcome
MEMS adherence, adjusted for the correct timing of doses
and at a cut-off of 95%, showed a speciﬁcity of 100% in
predicting virologic suppression (AUC 0.57; sensitivity
13%). For unadjusted MEMS, sensitivity was 27%, speci-
ﬁcity 47% and AUC 0.43.
Composite Measures of Adherence
In an attempt to ﬁnd an easy and cost-effective measure of
adherence, the value of the single measures as well as a
combined measure of adherence was assessed by creating
receiver-operating characteristics (ROC) curves, using
MEMS adherence greater than 95% as the reference. For
each combination of measures, an additive score was
developed (e.g. VAS adherence ? 3DR adherence). These
are shown in Table 4. The largest AUC was reached by a
combination of 3DR and VAS, the two subjective care-
giver-based measures (AUC = 0.62). The difference in
AUCs did not reach statistical signiﬁcance for any of the
additive scores (P[0.05 for all). Using a combination of
three measures did not result in larger AUCs, nor did it
show statistical signiﬁcance (P[0.05 for all).
Costing of Four Methods of Adherence Measurement
As shown in Table 5, the MEMS adherence measure was
considerably more expensive than any of the other meth-
ods. This was primarily due to the purchasing cost every
3 years ($120 per cap/bottle unit; the battery life limits the
length of use) but also due to the additional expected input
from the pharmacist (annual wage $37,341) and pharmacist
assistant (annual wage $8,487) in managing the adherence
measurement process. The average length of time taken by
a pharmacist assistant to measure adherence in the PR
method explains the higher costs for this method compared
to the VAS and PACTG questionnaire methods, which can
be administered by a counselor (annual wage $4,532).
Table 4 Sensitivity, speciﬁcity,
positive and negative predictive
value and area under curve for
all adherence measures in
predicting MEMS adherence
[95%
The AUC was calculated by
using continuous measures,
while sensitivity, speciﬁcity,
PPV and NPV were calculated
for the above listed cut-points
AUC Area under curve, MEMS
Medication event monitoring
system, VAS Visual analogue
scale, 3DR 3-Day recall based
on PACTG-questionnaire, PR
Pharmacy reﬁll, RS Measure of
returned syrup, PPV Positive
predictive value, NPV Negative
predictive value
Measure AUC Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
VAS[95% 0.60 100 13 11 100
VAS[80% 100 5 10 100
3DR[95% 0.57 100 10 10 100
3DR[80% 100 5 10 100
RS[95% 0.56 100 13 11 100
RS[80% 100 3 10 100
PR[95% 0.49 100 10 10 100
PR[80% 100 0 9 –
VAS ? 3DR 0.62 –
3DR ? RS 0.59 –
VAS ? RS 0.57 –
VAS ? PR 0.56 –
3DR ? PR 0.52 –
RS ? PR 0.48 –
VAS ? 3DR ? RS 0.60 –
VAS ? 3DR ? PR 0.58 –
3DR ? PR ? RS 0.53 –
VAS ? PR ? RS 0.52 –
Table 5 Annual per patient costs of adherence monitoring methods
Adherence monitoring
method
Resources Annual cost
per patient
1. MEMS bottle method MEMS equipment $46.30
Staff time $11.53
Total cost $57.83
2. Pharmacy Reﬁll Staff time $2.58
3. Visual Analogue Scale Staff time $0.19
4. Modiﬁed PACTG
questionnaire: 3DR
Staff time $0.39
MEMS Medication event monitoring system, PACTG Pediatric AIDS
clinical trials group, 3DR 3-Day recall
428 AIDS Behav (2011) 15:422–431
123Discussion
In this cohort of children on ART we sought to determine
the most practical and cost-effective method of measuring
adherence in a RLS. MEMS was used as the reference
method against which two subjective and two objective
adherence assessments were compared. Of note, adherence
as measured by MEMS (adjusted for dosing interval) in
this study correlated with virologic suppression, which
remained unchanged pre-and post-study.
Overall adherence by all measures was excellent: both
subjective measures (VAS and 3DR) showed a median
adherence of 100%. Overestimation of adherence is a
common issue with subjective measures, which is why they
are often not considered useful alone [31]. Objective
measures (PR and SR) however, had similarly high median
adherence values in this study. All of the subjective and
objective measures appeared to overestimate adherence
when compared to MEMS.
The adherence rates in this young age group are similar
to ﬁndings in older children [7], except for PR adherence,
which was higher in our cohort. It has recently been shown
that caregiver motivation and knowledge of ART are
important predictors of adherence [32],
The fact that adherence rates were not lower in our very
young cohort, where medication administration was further
complicated by liquid formulations, suggests that motiva-
tional factors are of higher predictive importance than
regimen complexity.
MEMS data showed that the timing of doses was often
deviant from prescription—a ﬁnding that no other adher-
ence measure could detect. Unfortunately, at an annual cost
of $57 per patient including equipment and staff time,
MEMS caps are not affordable in most RLS. While both
subjective measures are easy to use and low cost at less
than $0.40 per patients per annum per measure, neither
correlated signiﬁcantly with overall MEMS adherence.
Only VAS showed signiﬁcant correlation with timedM-
EMS—the correlation, however, was weak. Given the fact
that VAS showed very little variance, this correlation’s
relevance should be interpreted with caution. Similarly, the
objective measures showed poor correlation with MEMS.
Syrup returns were difﬁcult to manage and required more
staff time than simply calculating PR data.
For the objective measures, although PR has been shown
to be a highly effective means of monitoring adherence in
adults [18], in our study PR overestimated adherence when
compared to MEMS. This difference may be due to the
different dispensing practices for syrups versus pills. For
adults, exact numbers of pills can be counted and dis-
pensed, whereas syrups can usually only be dispensed
according to the manufacturers prepackaged volume. Since
the dose of antiretroviral drugs changes with patient weight
in children, no pharmacist is able to dispense an exact
amount of syrup. The other objective measure, syrup
returns, also overestimated adherence when compared to
MEMS, possibly due to liquid spillage at dosing times.
Another possibility is that of medication dumping—care-
givers might deliberately empty medication containers
before attending the clinic in order to appear adherent.
Regardless, although PR is not as useful a tool in children
as in adults, it is the more simple and cost effective mea-
sure if an objective method is to be used.
These results should be interpreted in light of several
limitations. Due to limited ﬁnancial and staff resources, we
were only able to follow mother–child dyads for a short
period of time, and it is possible that self-reported adher-
ence was inﬂated (relative to MEMS adherence) over this
short period. Overestimation of adherence by all measures
but PR could also have occurred through the Hawthorne
effect, due to the short monitoring period. It is also
important to note that we measured only one antiretroviral
drug of the regimen of three. Even though we included
virologic data from subsequent visits after the adherence-
monitoring period, the study cohort showed very little
heterogeneity in their virologic response, and this limits the
analyses. It is further noteworthy that the wider time frame
during which specimen were collected could have inﬂu-
enced results. It is also important to note the limitations of
our sample size—even though it is relatively large in
comparison with other pediatric MEMS studies and with
regards to our clinic population, its size is limiting in
interpreting the signiﬁcance of the detected associations
and the overall statistical power of the data.
MEMS can over- or underestimate adherence, and even
though we adjusted our data for these limitations, it cannot
be guaranteed that all the caregiver reports that the
adjustments were based on were correct.
Measuring adherence remains complex and elusive. The
data here does highlight some areas where more intensive
education should occur in the treatment support process:
training with regard to amount and method of dosing syr-
ups should be emphasized, as should timing of dosing.
Although MEMS gave realistic adherence data in our
study, no single adherence method is ideal. Our data sug-
gest that PR and VAS would give an inexpensive assess-
ment of objective and subjective adherence, but only VAS
showed any correlation with MEMS usage. It is unfortu-
nate that the expense of the best method renders it
unavailable in RLS. As MEMS is repeatedly shown to be
the best method of monitoring adherence, despite its lim-
itations, perhaps more effort should be directed at the
exploration of cheaper electronic alternatives for such RLS.
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